Tao Synergies Inc (TAOX)

$3.66 +0.05 (1.39%)
Market Cap 27.35M
Revenue (ttm) 300,000.00
Net Income (ttm) -28.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,580.00%
Debt to Equity Ratio 0.00
Volume 113,500
Avg Vol 138,382
Day's Range N/A - N/A
Shares Out 7.47M
Stochastic %K 51%
Beta 1.42
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. It focuses on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor and a decentralized blockchain network for machine learning and AI. The company was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. TAO Synergies Inc was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
EndGame1
EndGame1 Jul. 2 at 1:59 PM
$TAOX Liking the turn. $4 soon. "Bittensor Rises 7.7% on Exchange Listings, Revenue Milestones, and Payment Integration."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jul. 2 at 1:54 PM
$TAOX Adding mid $3's, Looking for 30% profit taking around $6, rest long.
0 · Reply
EndGame1
EndGame1 Jul. 1 at 5:44 PM
$TAOX I'm just waiting for my shares to get back to $10 again. Really hoping management added more $TAO.X coins recently. "Kraken Lists Seven Bittensor Subnet Alpha Tokens: Kraken announced listings for seven Bittensor subnet alpha tokens. This expands tradable access to the Bittensor ecosystem infrastructure, increasing accessibility for investors."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jun. 29 at 7:44 PM
$TAOX Wow! We are flying today!!!
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jun. 29 at 6:21 PM
$TAOX Nice!
0 · Reply
SnoopyPotter
SnoopyPotter Jun. 22 at 7:24 PM
$TAOX NEWS: TAO Synergies (TAOX) set to join Russell Microcap Index, expanding institutional access to Bittensor. A major win for $TAO.X holders and the broader ecosystem.
0 · Reply
EndGame1
EndGame1 Jun. 18 at 2:27 PM
$TAOX $TAO.X From $200 to $280, back down to $240. I guess that’s fair enough before next move up.
0 · Reply
EndGame1
EndGame1 Jun. 17 at 6:47 PM
$TAOX New Fed chairman is making positive changes. Market loves him and his changes.
0 · Reply
EndGame1
EndGame1 Jun. 17 at 2:15 PM
$TAOX "New Bittensor Proposal Transforms Validators into Fund Managers: A new Bittensor proposal aims to reconfigure validators, enabling them to operate in a capacity similar to fund managers, as reported by CoinDesk."
0 · Reply
green_going_up
green_going_up Jun. 17 at 5:45 AM
$TWAV they should be tapping the ATM to load up on $TAO.X and invest in subnets. Same with $TAOX. The entire point of these firms existing in the first place was to raise funds to invest in Bittensor and the Bittensor network. Yet, neither firm is active enough. Dilution works but only if the proceeds are invested in$TAO.X and its token price increases substantially. Otherwise, neither firm should be in business.
0 · Reply
Latest News on TAOX
TAO Synergies to join the Russell Microcap Index

2026-06-16T13:21:36.000Z - 18 days ago

TAO Synergies to join the Russell Microcap Index

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

Jun 16, 2026, 9:15 AM EDT - 18 days ago

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 8 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 8 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 8 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

TAO Synergies files to sell 22.3M shares of common stock for holders

2025-11-12T21:22:16.000Z - 8 months ago

TAO Synergies files to sell 22.3M shares of common stock for holders

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 8 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

2025-11-04T14:20:39.000Z - 8 months ago

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 8 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies reports total TAO increased to 54,058 tokens

2025-10-20T13:20:22.000Z - 9 months ago

TAO Synergies reports total TAO increased to 54,058 tokens

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 9 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies announces $11M private placement

2025-10-13T21:15:14.000Z - 9 months ago

TAO Synergies announces $11M private placement

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 9 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 10 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 10 months ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 11 months ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies files $100M mixed securities shelf

2025-08-14T20:55:13.000Z - 11 months ago

TAO Synergies files $100M mixed securities shelf

TAO Synergies acquires $10M of Bittensor

2025-07-17T13:21:08.000Z - 1 year ago

TAO Synergies acquires $10M of Bittensor

TAO Synergies files to sell 5.04M shares of common stock for holders

2025-07-11T21:05:08.000Z - 1 year ago

TAO Synergies files to sell 5.04M shares of common stock for holders

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 1 year ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 2 years ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 3 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 4 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 5 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 5 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

EndGame1
EndGame1 Jul. 2 at 1:59 PM
$TAOX Liking the turn. $4 soon. "Bittensor Rises 7.7% on Exchange Listings, Revenue Milestones, and Payment Integration."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jul. 2 at 1:54 PM
$TAOX Adding mid $3's, Looking for 30% profit taking around $6, rest long.
0 · Reply
EndGame1
EndGame1 Jul. 1 at 5:44 PM
$TAOX I'm just waiting for my shares to get back to $10 again. Really hoping management added more $TAO.X coins recently. "Kraken Lists Seven Bittensor Subnet Alpha Tokens: Kraken announced listings for seven Bittensor subnet alpha tokens. This expands tradable access to the Bittensor ecosystem infrastructure, increasing accessibility for investors."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jun. 29 at 7:44 PM
$TAOX Wow! We are flying today!!!
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Jun. 29 at 6:21 PM
$TAOX Nice!
0 · Reply
SnoopyPotter
SnoopyPotter Jun. 22 at 7:24 PM
$TAOX NEWS: TAO Synergies (TAOX) set to join Russell Microcap Index, expanding institutional access to Bittensor. A major win for $TAO.X holders and the broader ecosystem.
0 · Reply
EndGame1
EndGame1 Jun. 18 at 2:27 PM
$TAOX $TAO.X From $200 to $280, back down to $240. I guess that’s fair enough before next move up.
0 · Reply
EndGame1
EndGame1 Jun. 17 at 6:47 PM
$TAOX New Fed chairman is making positive changes. Market loves him and his changes.
0 · Reply
EndGame1
EndGame1 Jun. 17 at 2:15 PM
$TAOX "New Bittensor Proposal Transforms Validators into Fund Managers: A new Bittensor proposal aims to reconfigure validators, enabling them to operate in a capacity similar to fund managers, as reported by CoinDesk."
0 · Reply
green_going_up
green_going_up Jun. 17 at 5:45 AM
$TWAV they should be tapping the ATM to load up on $TAO.X and invest in subnets. Same with $TAOX. The entire point of these firms existing in the first place was to raise funds to invest in Bittensor and the Bittensor network. Yet, neither firm is active enough. Dilution works but only if the proceeds are invested in$TAO.X and its token price increases substantially. Otherwise, neither firm should be in business.
0 · Reply
EndGame1
EndGame1 Jun. 16 at 2:37 PM
$TAOX Fools they are for selling this cheap.
0 · Reply
EndGame1
EndGame1 Jun. 16 at 1:50 AM
$TAOX On June 10 2026 TAO Synergie's $TAO.X March 31 coin holdings were worth $16,277,580.00. As of today, they are worth $21,785,650.00. The share price has barely moved. This will have positive changes if TAO holds this week. News Friday of government involvement in $BTC.X changed crypto forever.
1 · Reply
EndGame1
EndGame1 Jun. 16 at 1:30 AM
$TAOX Balance of $TAO.X 12-31-25...81,319 coins. 3-31-26= 82,210 coins. "As of March 31, 2026, the Company had approximately $3.6 million in cash and cash equivalents and approximately $25.2 million in digital asset value."
0 · Reply
green_going_up
green_going_up Jun. 15 at 10:42 PM
$TAOX Too bad James and the Board FAILED to have capital flexibility to be able to add to $TAO.X when it fell below $200; should have at least 100k tokens by now. Seriously, what does James do all day besides tout stocks for his newsletter and spend time on "X"?
2 · Reply
EndGame1
EndGame1 Jun. 15 at 6:29 PM
$TAOX Share price is crazy cheap. $TAO.X coin made a 40% jump from last week and Bittensor barely moved. Will be $5 by next week. $DGXX $SOFI $OPEN
0 · Reply
Linkinlogs
Linkinlogs Jun. 15 at 1:33 PM
$TWAV $TAOX
0 · Reply
SnoopyPotter
SnoopyPotter Jun. 15 at 12:55 PM
$TAOX Just a remindere that there is no direct 1:1 correlation with Tao and $TAOX (TAO Synergies Inc. stock). TAOX is a Nasdaq-listed company that's basically a public vehicle/holder focused on Bittensor — they hold a bunch of TAO in treasury, stake it, etc., positioning as a pure-play on decentralized AI via TAO. taosynergies.com But stock price vs. underlying crypto can diverge for a bunch of reasons:Market structure: TAOX is a micro-cap stock (~$27M market cap, lower liquidity, trading around $3.60–$3.90 lately). It reacts to equity market flows, news about the company itself, broader Nasdaq sentiment, etc. finance.yahoo.com Premium/discount to NAV: TAOX's value is tied to its TAO holdings, but it can trade at a premium or discount depending on investor sentiment, dilution risks, operational updates, or how much people trust the execution.
1 · Reply
SnoopyPotter
SnoopyPotter Jun. 15 at 12:39 PM
$TAOX History snapshot:July 2025: Started with ~29,899 TAO (~$10M purchase). August 2025: Grew to ~42,111 TAO. October 2025: Reached 54,058 TAO via buys + staking rewards. coingecko.com No newer SEC filings or press releases show a change beyond this (as of the latest available data). Companies like this often report holdings periodically rather than daily.For the absolute freshest number, check:TAO Synergies IR: ir.taosynergies.com Their X: @TAOSynergies CoinGecko Treasury page or upcoming 10-Q filings.
1 · Reply
SnoopyPotter
SnoopyPotter Jun. 15 at 12:32 PM
$TAOX Why Does TAO Price Matter to TAOX? When TAO goes up → TAOX’s treasury value rises → investors often bid up the stock. But it’s not a 1:1 mirror. Recent example: TAO touching $280 doesn’t automatically send TAOX flying.Key Reasons for No Direct CorrelationStock vs. Crypto dynamics: Stocks trade only during market hours, react to Nasdaq sentiment, dilution fears, and company-specific news. Liquidity & size: TAOX is tiny and volatile. Low trading volume means big swings from small buys/sells. Premium / Discount to NAV: The stock can trade at a premium (hype) or discount (doubt) relative to the value of the TAO they hold. Other factors: Share issuance/dilution, broader market moves, regulatory news, staking rewards, or just how much faith people have in management’s execution. Company history: Originally a biotech firm (Synaptogenix) that pivoted hard into TAO in 2025. Current snapshot (as of mid-June 2026):TAO ≈ $270–$280 TAOX ≈ $3.60–$3.80 range (micro-cap, watch volume closely)
0 · Reply
Jimmybelanger3
Jimmybelanger3 Jun. 15 at 1:38 AM
$TAOX
0 · Reply
manolo331
manolo331 Jun. 14 at 6:48 AM
$TAOX
1 · Reply
EndGame1
EndGame1 Jun. 14 at 2:42 AM
$TAOX “14 June 2026 | 02:41 A single government directive just reminded the world that centralized AI can be switched off. Bittensor's TAO token surged as capital looked for infrastructure that can't.”
0 · Reply